It’s the first screening device the FDA has authorized that doesn’t need a clinician’s interpretation to look for a particular condition. In other news, the agency also is going to relax its review of next-generation sequencing tests. https://khn.org/morning-breakout/software-that-uses-artificial-intelligence-to-screen-eyes-for-diabetes-damage-approved-by-fda/
Boehringer Ingelheim and Lilly expand heart failure program for Jardiance® with new exercise capacity trials https://investor.lilly.com/releasedetail.cfm?ReleaseID=1059806
Intense competition in the diabetes drugs market has pushed manufacturers to search for ways to gain an edge, including value-based deals with payers. https://www.biopharmadive.com/news/boehringer-strikes-jardiance-outcomes-deal-with-prime-pbm/516026/
Pharmaceutical companies in the diabetes market are all investing in tech to help doctors and patients manage the
The post Lilly partners with Rimidi on digital diabetes management tool appeared first on Pharmaphorum. https://pharmaphorum.com/news/lilly-develop-digital-diabetes-management-tool-rimidi/
Fitbit fitness tracker data will integrate into One Drop Mobile.
The post One Drop and Fitbit to integrate diabetes and activity data appeared first on Pharmaphorum. https://pharmaphorum.com/news/one-drop-fitbit-diabetes/
Dexcom G5 Mobile data will be displayed on Fitbit’s Ionic smartwatch.
The post Fitbit and Dexcom to bring diabetes data to Ionic smartwatch appeared first on Pharmaphorum. https://pharmaphorum.com/news/fitbit-dexcom-ionic-smartwatch/
Novo Nordisk and Roche are two examples of drugmakers that are turning to digital-health startups to better engage with patients and mine valuable real-world evidence. http://www.mmm-online.com/technology/diabetes-drugmakers-partner-with-mobile-startups-to-boost-patient-engagement/article/676290/
Roche and mySugr announced today that the two partners have signed an agreement under which Roche acquired all shares of mySugr GmbH. http://www.roche.com/media/store/releases/med-cor-2017-06-30.htm
COPENHAGEN (Reuters) – Danish drugmaker Novo Nordisk said on Friday a phase 2 trial for its big hope in tackling obesity, an improved GLP-1 drug called semaglutide, showed a weight loss of up to 13.8 percent in people with severe conditions.
US regulatory advisors are backing the claim that Novo Nordisks’ Victoza reduces cardiovascular risk in patients with diabetes. http://www.pharmatimes.com/news/novo_gets_us_backing_for_victoza_cardiovascular_data_1196325